<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.urologytimes.com/view/preclinical-data-show-potential-of-cd46-targeted-combination-therapy-in-prostate-cancer</loc><lastmod>2026-04-22T20:00:44.787Z</lastmod><news:news><news:publication_date>2026-04-22T20:00:44.787Z</news:publication_date>
        <news:title><![CDATA[Preclinical data show potential of CD46-targeted combination therapy in prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/cabozantinib-plus-nivolumab-shows-encouraging-activity-in-mcrpc</loc><lastmod>2026-04-22T17:20:34.628Z</lastmod><news:news><news:publication_date>2026-04-22T17:20:34.628Z</news:publication_date>
        <news:title><![CDATA[Cabozantinib plus nivolumab shows encouraging activity in mCRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/when-should-post-vasectomy-semen-analysis-be-performed-</loc><lastmod>2026-04-22T14:55:00Z</lastmod><news:news><news:publication_date>2026-04-22T14:55:00Z</news:publication_date>
        <news:title><![CDATA[When should post-vasectomy semen analysis be performed?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/eau-2026-testicular-cancer-guideline-reflects-key-updates-in-diagnosis-and-management</loc><lastmod>2026-04-21T17:30:50.696Z</lastmod><news:news><news:publication_date>2026-04-21T17:30:50.696Z</news:publication_date>
        <news:title><![CDATA[EAU 2026 Testicular Cancer Guideline reflects key updates in diagnosis and management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/neha-vapiwala-md-on-intensifying-radiotherapy-in-prostate-cancer</loc><lastmod>2026-04-21T15:00:00Z</lastmod><news:news><news:publication_date>2026-04-21T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Neha Vapiwala, MD, on intensifying radiotherapy in prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/litespark-012-trial-misses-dual-primary-end-points-in-advanced-ccrcc</loc><lastmod>2026-04-21T12:55:00Z</lastmod><news:news><news:publication_date>2026-04-21T12:55:00Z</news:publication_date>
        <news:title><![CDATA[LITESPARK-012 trial misses dual primary end points in advanced ccRCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/operational-best-practices-to-improve-access-in-mcrpc</loc><lastmod>2026-04-21T12:30:00Z</lastmod><news:news><news:publication_date>2026-04-21T12:30:00Z</news:publication_date>
        <news:title><![CDATA[Operational Best Practices To Improve Access in mCRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/psma-targeted-t-cell-engager-enters-phase-1-testing-in-mcrpc</loc><lastmod>2026-04-20T18:30:00Z</lastmod><news:news><news:publication_date>2026-04-20T18:30:00Z</news:publication_date>
        <news:title><![CDATA[PSMA-targeted T-cell engager enters phase 1 testing in mCRPC ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/darlifarnib-plus-cabozantinib-shows-early-activity-in-ccrcc</loc><lastmod>2026-04-20T16:30:00Z</lastmod><news:news><news:publication_date>2026-04-20T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Darlifarnib plus cabozantinib shows early activity in ccRCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-grants-priority-review-to-ev-plus-pembrolizumab-for-cisplatin-eligible-mibc</loc><lastmod>2026-04-20T11:27:52.372Z</lastmod><news:news><news:publication_date>2026-04-20T11:27:52.372Z</news:publication_date>
        <news:title><![CDATA[FDA grants priority review to EV plus pembrolizumab for cisplatin-eligible MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/experts-react-to-fda-s-potential-pathway-for-trt-label-expansion</loc><lastmod>2026-04-17T19:00:00Z</lastmod><news:news><news:publication_date>2026-04-17T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Experts react to FDA’s potential pathway for TRT label expansion]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/how-to-avoid-and-how-to-manage-complications-of-radical-cystectomy</loc><lastmod>2026-04-17T14:15:30.294Z</lastmod><news:news><news:publication_date>2026-04-17T14:15:30.294Z</news:publication_date>
        <news:title><![CDATA[How to avoid and how to manage complications of radical cystectomy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-uroonc-minute-keynote-b15-and-perioperative-therapy-in-mibc-with-alfonso-gomez-de-lia-o-lista</loc><lastmod>2026-04-17T13:35:00Z</lastmod><news:news><news:publication_date>2026-04-17T13:35:00Z</news:publication_date>
        <news:title><![CDATA[The UroOnc Minute: KEYNOTE-B15 and Perioperative Therapy in MIBC, with Dr. Alfonso Gómez de Liaño Lista]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/integrating-psma-pet-into-advanced-prostate-cancer-care</loc><lastmod>2026-04-17T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-17T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Integrating PSMA PET into Advanced Prostate Cancer Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/eau-updates-testicular-cancer-guideline-with-focus-on-de-intensification</loc><lastmod>2026-04-16T19:40:06.437Z</lastmod><news:news><news:publication_date>2026-04-16T19:40:06.437Z</news:publication_date>
        <news:title><![CDATA[EAU updates Testicular Cancer Guideline with focus on de-intensification ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-signals-potential-pathway-for-testosterone-therapy-label-expansion</loc><lastmod>2026-04-16T16:45:00Z</lastmod><news:news><news:publication_date>2026-04-16T16:45:00Z</news:publication_date>
        <news:title><![CDATA[FDA signals potential pathway for testosterone therapy label expansion ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/kyle-rose-md-on-optimizing-lymph-node-dissection-in-penile-cancer</loc><lastmod>2026-04-16T13:15:00Z</lastmod><news:news><news:publication_date>2026-04-16T13:15:00Z</news:publication_date>
        <news:title><![CDATA[Kyle Rose, MD, on optimizing lymph node dissection in penile cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/interpreting-phase-3-trial-evidence-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-04-16T12:05:00Z</lastmod><news:news><news:publication_date>2026-04-16T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Interpreting Phase 3 Trial Evidence in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/central-nervous-system-effects-and-treatment-selection-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-04-16T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-16T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Central Nervous System Effects and Treatment Selection in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pembrolizumab-plus-chemoradiation-shows-feasibility-for-muscle-invasive-bladder-cancer</loc><lastmod>2026-04-15T16:30:00Z</lastmod><news:news><news:publication_date>2026-04-15T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Pembrolizumab plus chemoradiation shows feasibility in muscle-invasive bladder cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/akanksha-mehta-md-on-vas-isolation-and-vas-occlusion-techniques</loc><lastmod>2026-04-15T14:30:00Z</lastmod><news:news><news:publication_date>2026-04-15T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Akanksha Mehta, MD, on vas isolation and vas occlusion techniques ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fred-saad-md-on-darolutamide-outcomes-across-comorbidity-burdens</loc><lastmod>2026-04-14T16:20:00Z</lastmod><news:news><news:publication_date>2026-04-14T16:20:00Z</news:publication_date>
        <news:title><![CDATA[Fred Saad, MD, on darolutamide outcomes across comorbidity burdens]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/hugo-ras-digital-platform-enables-ai-driven-case-review-and-telementoring</loc><lastmod>2026-04-14T13:31:55.557Z</lastmod><news:news><news:publication_date>2026-04-14T13:31:55.557Z</news:publication_date>
        <news:title><![CDATA[Hugo RAS digital platform enables AI-driven case review and telementoring]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-grants-breakthrough-device-designation-to-urine-based-multi-cancer-early-detection-test</loc><lastmod>2026-04-14T13:15:00Z</lastmod><news:news><news:publication_date>2026-04-14T13:15:00Z</news:publication_date>
        <news:title><![CDATA[FDA grants Breakthrough Device Designation to urine-based multi-cancer early detection test]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pearls-perspectives-bridging-medicine-and-intimacy-with-polly-rodriguez</loc><lastmod>2026-04-14T12:30:00Z</lastmod><news:news><news:publication_date>2026-04-14T12:30:00Z</news:publication_date>
        <news:title><![CDATA[Pearls & Perspectives: Bridging Medicine and Intimacy, with Polly Rodriguez]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/navigating-prior-authorization-denials-and-appeals-in-mcrpc</loc><lastmod>2026-04-14T12:15:00Z</lastmod><news:news><news:publication_date>2026-04-14T12:15:00Z</news:publication_date>
        <news:title><![CDATA[Navigating Prior Authorization Denials and Appeals in mCRPC ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/meri-margaret-deoudes-on-patient-engagement-in-bladder-cancer-care</loc><lastmod>2026-04-13T19:25:00Z</lastmod><news:news><news:publication_date>2026-04-13T19:25:00Z</news:publication_date>
        <news:title><![CDATA[Meri-Margaret Deoudes on patient engagement in bladder cancer care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/daniel-george-md-on-pros-and-tolerability-data-from-capitello-281</loc><lastmod>2026-04-13T17:00:00Z</lastmod><news:news><news:publication_date>2026-04-13T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Daniel George, MD, on PROs and tolerability data from CAPItello-281]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/vir-5500-enters-expansion-cohorts-in-phase-1-trial-for-metastatic-prostate-cancer</loc><lastmod>2026-04-13T14:45:00Z</lastmod><news:news><news:publication_date>2026-04-13T14:45:00Z</news:publication_date>
        <news:title><![CDATA[VIR-5500 enters expansion cohorts in phase 1 trial for metastatic prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/minas-economides-md-on-kim-1-and-emerging-targets-in-kidney-cancer</loc><lastmod>2026-04-11T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-11T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Minas Economides, MD, on KIM-1 and emerging targets in kidney cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-uroonc-minute-salvage-focal-therapy-for-radiorecurrent-prostate-cancer-with-alexander-light-mbbs</loc><lastmod>2026-04-10T17:00:00Z</lastmod><news:news><news:publication_date>2026-04-10T17:00:00Z</news:publication_date>
        <news:title><![CDATA[The UroOnc Minute: Salvage Focal Therapy for Radiorecurrent Prostate Cancer, with Alexander Light, MBBS]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/jennifer-miles-thomas-md-on-surgeon-app-collaboration-in-urology</loc><lastmod>2026-04-10T16:45:00Z</lastmod><news:news><news:publication_date>2026-04-10T16:45:00Z</news:publication_date>
        <news:title><![CDATA[Jennifer Miles-Thomas, MD, on surgeon–APP collaboration in urology]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/advances-in-sacral-neuromodulation-support-more-individualized-treatment-pathways</loc><lastmod>2026-04-10T15:10:00Z</lastmod><news:news><news:publication_date>2026-04-10T15:10:00Z</news:publication_date>
        <news:title><![CDATA[Advances in sacral neuromodulation support more individualized treatment pathways]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-expert-approach-app-leadership-and-clinical-empowerment-with-melissa-kestler-dnp-fnp-bc</loc><lastmod>2026-04-10T12:30:00Z</lastmod><news:news><news:publication_date>2026-04-10T12:30:00Z</news:publication_date>
        <news:title><![CDATA[The Expert APProach: APP Leadership and Clinical Empowerment, with Melissa Kestler, DNP, FNP-BC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/clinical-reliability-of-psma-pet-in-advanced-prostate-cancer</loc><lastmod>2026-04-10T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-10T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Reliability of PSMA PET in Advanced Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/bullseye-177lu-psma-617-may-delay-disease-progression-in-oligometastatic-hspc</loc><lastmod>2026-04-09T19:00:10.226Z</lastmod><news:news><news:publication_date>2026-04-09T19:00:10.226Z</news:publication_date>
        <news:title><![CDATA[BULLSEYE: 177Lu-PSMA-617 may delay disease progression in oligometastatic HSPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/cvac-2-0-outperforms-fans-sheath-for-larger-stone-fragment-clearance-in-bench-model</loc><lastmod>2026-04-09T16:30:50.966Z</lastmod><news:news><news:publication_date>2026-04-09T16:30:50.966Z</news:publication_date>
        <news:title><![CDATA[CVAC 2.0 outperforms FANS sheath for larger stone fragment clearance in bench model]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/phase-3-trial-to-evaluate-gut-microbiome-intervention-in-renal-cell-carcinoma</loc><lastmod>2026-04-09T16:30:00Z</lastmod><news:news><news:publication_date>2026-04-09T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Phase 3 trial to evaluate gut microbiome intervention in renal cell carcinoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/drug-interactions-and-polypharmacy-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-04-09T12:05:00Z</lastmod><news:news><news:publication_date>2026-04-09T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Drug Interactions and Polypharmacy in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/long-term-tolerability-and-ar-pathway-inhibitor-selection-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-04-09T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-09T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Long Term Tolerability and AR Pathway Inhibitor Selection in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/akanksha-mehta-md-on-pre-operative-counseling-for-vasectomy</loc><lastmod>2026-04-09T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-09T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Akanksha Mehta, MD, on pre-operative counseling for vasectomy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/stacy-loeb-md-on-emerging-environmental-data-in-prostate-cancer</loc><lastmod>2026-04-08T19:30:00Z</lastmod><news:news><news:publication_date>2026-04-08T19:30:00Z</news:publication_date>
        <news:title><![CDATA[Stacy Loeb, MD, on emerging environmental data in prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/virtual-reality-may-enhance-consenting-process-for-shock-wave-lithotripsy</loc><lastmod>2026-04-08T18:00:00Z</lastmod><news:news><news:publication_date>2026-04-08T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Virtual reality may enhance consenting process for shock wave lithotripsy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/utdna-guided-mrd-assessment-may-predict-response-to-bcg-in-nmibc</loc><lastmod>2026-04-08T15:05:11.262Z</lastmod><news:news><news:publication_date>2026-04-08T15:05:11.262Z</news:publication_date>
        <news:title><![CDATA[utDNA–guided MRD assessment may predict response to BCG in NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/how-biomarkers-and-akt-inhibition-are-becoming-part-of-the-mhspc-landscape</loc><lastmod>2026-04-08T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-08T12:00:00Z</news:publication_date>
        <news:title><![CDATA[How Biomarkers and AKT Inhibition Are Becoming Part of the mHSPC Landscape]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/michelle-van-kuiken-md-highlights-strategies-for-setting-professional-boundaries</loc><lastmod>2026-04-08T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-08T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Michelle Van Kuiken, MD, highlights strategies for setting professional boundaries]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/optimizing-treatment-with-intravesical-drug-releasing-systems-in-nmibc</loc><lastmod>2026-04-07T17:15:00Z</lastmod><news:news><news:publication_date>2026-04-07T17:15:00Z</news:publication_date>
        <news:title><![CDATA[Optimizing treatment with intravesical drug-releasing systems in NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/jonathan-anker-md-highlights-response-guided-bladder-preservation-strategy-in-mibc</loc><lastmod>2026-04-07T14:30:00Z</lastmod><news:news><news:publication_date>2026-04-07T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Jonathan Anker, MD, highlights response-guided bladder preservation strategy in MIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/high-powered-lasers-expand-ureteroscopic-options-for-patients-with-kidney-stones</loc><lastmod>2026-04-07T13:36:46.804Z</lastmod><news:news><news:publication_date>2026-04-07T13:36:46.804Z</news:publication_date>
        <news:title><![CDATA[High-powered lasers expand ureteroscopic options for patients with kidney stones]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/initiating-a-successful-prior-authorization-in-mcrpc</loc><lastmod>2026-04-07T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-07T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Initiating a Successful Prior Authorization in mCRPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/metformin-elevates-anti-obesogenic-metabolite-lac-phe-in-prostate-cancer</loc><lastmod>2026-04-06T20:30:00Z</lastmod><news:news><news:publication_date>2026-04-06T20:30:00Z</news:publication_date>
        <news:title><![CDATA[Metformin elevates anti-obesogenic metabolite Lac-Phe in prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/daniel-george-md-on-capivasertib-plus-abiraterone-in-pten-deficient-mhspc</loc><lastmod>2026-04-06T17:45:00Z</lastmod><news:news><news:publication_date>2026-04-06T17:45:00Z</news:publication_date>
        <news:title><![CDATA[Daniel George, MD, on capivasertib plus abiraterone in PTEN-deficient mHSPC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-issues-warning-letter-to-immunitybio-over-misleading-promotion-of-nai</loc><lastmod>2026-04-06T16:15:00Z</lastmod><news:news><news:publication_date>2026-04-06T16:15:00Z</news:publication_date>
        <news:title><![CDATA[FDA issues warning letter to ImmunityBio over misleading promotion of NAI ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/mcspc-management-doublet-triplet-and-the-role-of-arsis</loc><lastmod>2026-04-06T15:00:00Z</lastmod><news:news><news:publication_date>2026-04-06T15:00:00Z</news:publication_date>
        <news:title><![CDATA[mCSPC management: Doublet, triplet, and the role of ARPIs]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/2026-aua-vasectomy-guideline-key-updates-and-clinical-faqs</loc><lastmod>2026-04-03T20:26:03.904Z</lastmod><news:news><news:publication_date>2026-04-03T20:26:03.904Z</news:publication_date>
        <news:title><![CDATA[2026 AUA Vasectomy Guideline: Key updates and clinical FAQs]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/alexandra-drakaki-md-on-managing-peripheral-neuropathy-on-enfortumab-vedotin</loc><lastmod>2026-04-03T17:10:36.257Z</lastmod><news:news><news:publication_date>2026-04-03T17:10:36.257Z</news:publication_date>
        <news:title><![CDATA[Alexandra Drakaki, MD, on managing peripheral neuropathy on enfortumab vedotin]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-uroonc-minute-litespark-022-and-adjuvant-therapy-in-ccrcc-with-wesley-yip-md</loc><lastmod>2026-04-03T14:50:00Z</lastmod><news:news><news:publication_date>2026-04-03T14:50:00Z</news:publication_date>
        <news:title><![CDATA[The UroOnc Minute: LITESPARK-022 and Adjuvant Therapy in ccRCC, with Wesley Yip, MD]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/clinical-considerations-for-psma-pet-agents-in-advanced-prostate-cancer</loc><lastmod>2026-04-03T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-03T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Considerations for PSMA PET Agents in Advanced Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/david-morris-md-discusses-significance-of-early-elution-with-intravesical-drug-systems</loc><lastmod>2026-04-02T17:58:00.605Z</lastmod><news:news><news:publication_date>2026-04-02T17:58:00.605Z</news:publication_date>
        <news:title><![CDATA[David Morris, MD, discusses significance of early elution with intravesical drug system]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/cms-issues-permanent-j-code-to-gemcitabine-intravesical-system</loc><lastmod>2026-04-02T16:05:00Z</lastmod><news:news><news:publication_date>2026-04-02T16:05:00Z</news:publication_date>
        <news:title><![CDATA[CMS issues permanent J-code to gemcitabine intravesical system ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/giulia-almiron-da-r-soares-discusses-factors-shaping-women-s-interest-in-urology</loc><lastmod>2026-04-02T13:47:23.913Z</lastmod><news:news><news:publication_date>2026-04-02T13:47:23.913Z</news:publication_date>
        <news:title><![CDATA[Giulia Almiron da R. Soares discusses factors shaping women’s interest in urology]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/selecting-androgen-receptor-pathway-inhibitors-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-04-02T12:05:00Z</lastmod><news:news><news:publication_date>2026-04-02T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Selecting Androgen Receptor Pathway Inhibitors in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/patient-specific-factors-guiding-treatment-selection-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-04-02T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-02T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Patient Specific Factors Guiding Treatment Selection in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/prostate-cancer-biomarkers-improve-detection-while-reducing-unnecessary-biopsies</loc><lastmod>2026-04-02T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-02T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Prostate cancer biomarkers improve detection while reducing unnecessary biopsies]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/christopher-pieczonka-md-on-best-practices-with-intravesical-drug-delivery-systems</loc><lastmod>2026-04-01T19:30:00Z</lastmod><news:news><news:publication_date>2026-04-01T19:30:00Z</news:publication_date>
        <news:title><![CDATA[Christopher Pieczonka, MD, on best practices with intravesical drug delivery systems]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-updates-in-urology-march-2026</loc><lastmod>2026-04-01T16:30:00Z</lastmod><news:news><news:publication_date>2026-04-01T16:30:00Z</news:publication_date>
        <news:title><![CDATA[FDA updates in urology: March 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/trial-launches-of-edison-histotripsy-system-for-benign-prostatic-hyperplasia</loc><lastmod>2026-04-01T14:30:00Z</lastmod><news:news><news:publication_date>2026-04-01T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Trial launches of Edison Histotripsy System for benign prostatic hyperplasia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/monotherapies-for-treatment-of-high-risk-biochemical-recurrent-prostate-cancer</loc><lastmod>2026-04-01T12:15:00Z</lastmod><news:news><news:publication_date>2026-04-01T12:15:00Z</news:publication_date>
        <news:title><![CDATA[Monotherapies for Treatment of High-Risk Biochemical Recurrent Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/treatment-strategies-with-androgen-receptor-pathway-inhibitors-in-castration-sensitive-prostate-cancer</loc><lastmod>2026-04-01T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-01T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Treatment Strategies with Androgen Receptor Pathway Inhibitors in Castration-Sensitive Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/os-and-adverse-events-observed-in-capitello-281</loc><lastmod>2026-04-01T12:00:00Z</lastmod><news:news><news:publication_date>2026-04-01T12:00:00Z</news:publication_date>
        <news:title><![CDATA[OS and Adverse Events Observed in CAPItello-281]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/top-10-urology-headlines-you-missed-in-q1-2026</loc><lastmod>2026-04-01T10:00:00Z</lastmod><news:news><news:publication_date>2026-04-01T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Top 10 urology headlines you missed in Q1 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/regulatory-recap-fda-approvals-in-urology-from-q1-of-2026</loc><lastmod>2026-03-31T18:45:00Z</lastmod><news:news><news:publication_date>2026-03-31T18:45:00Z</news:publication_date>
        <news:title><![CDATA[Regulatory recap: FDA approvals in urology from Q1 of 2026 ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/james-r-porter-md-on-how-the-hugo-ras-system-s-energy-architecture-differs-from-prior-platforms</loc><lastmod>2026-03-31T16:54:31.879Z</lastmod><news:news><news:publication_date>2026-03-31T16:54:31.879Z</news:publication_date>
        <news:title><![CDATA[James R. Porter, MD, on how the Hugo RAS system’s energy architecture differs from prior platforms]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-clears-neuromuscular-stimulation-device-for-post-prostatectomy-incontinence</loc><lastmod>2026-03-31T14:10:28.531Z</lastmod><news:news><news:publication_date>2026-03-31T14:10:28.531Z</news:publication_date>
        <news:title><![CDATA[FDA clears neuromuscular stimulation device for post-prostatectomy incontinence]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/transdermal-estradiol-patches-positioned-as-adt-alternative-for-prostate-cancer</loc><lastmod>2026-03-31T10:00:00Z</lastmod><news:news><news:publication_date>2026-03-31T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Transdermal estradiol patches positioned as ADT alternative for prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/phase-1-study-launches-of-anti-klk3-monoclonal-antibody-for-advanced-prostate-cancer</loc><lastmod>2026-03-30T18:21:06.359Z</lastmod><news:news><news:publication_date>2026-03-30T18:21:06.359Z</news:publication_date>
        <news:title><![CDATA[Phase 1 study launches of anti-KLK3 monoclonal antibody for advanced prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/matthias-saar-md-on-inductive-hormonal-therapy-for-t4-prostate-cancer</loc><lastmod>2026-03-30T16:06:45.868Z</lastmod><news:news><news:publication_date>2026-03-30T16:06:45.868Z</news:publication_date>
        <news:title><![CDATA[Matthias Saar, MD, on inductive hormonal therapy for T4 prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-grants-clearance-to-asurys-fluid-management-system-for-endoscopic-urologic-procedures</loc><lastmod>2026-03-30T13:10:58.743Z</lastmod><news:news><news:publication_date>2026-03-30T13:10:58.743Z</news:publication_date>
        <news:title><![CDATA[FDA grants clearance to Asurys Fluid Management System for endoscopic urologic procedures ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/prostate-cancer-working-group-4-redefines-trial-frameworks-in-era-of-psma-pet-and-precision-oncology</loc><lastmod>2026-03-30T12:00:00Z</lastmod><news:news><news:publication_date>2026-03-30T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Prostate Cancer Working Group 4 redefines trial frameworks in era of PSMA-PET and precision oncology]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/oral-selective-fgfr3-inhibition-in-urothelial-carcinoma-opportunities-in-intermediate-risk-non-muscle-invasive-bladder-cancer-and-low-grade-upper-tract-urothelial-carcinoma</loc><lastmod>2026-03-30T12:00:00Z</lastmod><news:news><news:publication_date>2026-03-30T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Oral Selective FGFR3 Inhibition in Urothelial Carcinoma: Opportunities in Intermediate Risk Non-Muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/biomarkers-in-nmibc-promise-without-clinical-utility-yet</loc><lastmod>2026-03-30T10:00:00Z</lastmod><news:news><news:publication_date>2026-03-30T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Biomarkers in NMIBC: Promise without clinical utility yet]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/meri-margaret-deoudes-highlights-bcan-s-new-faces-of-bladder-cancer-survey</loc><lastmod>2026-03-28T10:00:00Z</lastmod><news:news><news:publication_date>2026-03-28T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Meri-Margaret Deoudes highlights BCAN’s New Faces of Bladder Cancer survey]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/what-urologists-can-expect-in-q2-of-2026</loc><lastmod>2026-03-27T18:30:00Z</lastmod><news:news><news:publication_date>2026-03-27T18:30:00Z</news:publication_date>
        <news:title><![CDATA[What urologists can expect in Q2 of 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-uroonc-minute-biparametric-vs-multiparametric-mri-for-prostate-cancer-detection-with-veeru-kasivisvanathan-mbbs-msc-phd-frcs</loc><lastmod>2026-03-27T16:05:46.193Z</lastmod><news:news><news:publication_date>2026-03-27T16:05:46.193Z</news:publication_date>
        <news:title><![CDATA[The UroOnc Minute: Biparametric vs multiparametric MRI for prostate cancer detection, with Veeru Kasivisvanathan, MBBS, MSc, PhD, FRCS]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/the-silent-epidemic-aacu-and-man-vs-prostate-call-for-a-national-pivot-toward-bladder-health</loc><lastmod>2026-03-27T13:14:34.828Z</lastmod><news:news><news:publication_date>2026-03-27T13:14:34.828Z</news:publication_date>
        <news:title><![CDATA[The silent epidemic: AACU and Man vs Prostate call for a national pivot toward bladder health]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/expanding-clinical-use-of-psma-pet-in-advanced-prostate-cancer</loc><lastmod>2026-03-27T12:00:00Z</lastmod><news:news><news:publication_date>2026-03-27T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Expanding Clinical Use of PSMA PET in Advanced Prostate Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/pearls-perspectives-rethinking-uroflowmetry-with-innovation-with-bishara-korkor-ms</loc><lastmod>2026-03-27T12:00:00Z</lastmod><news:news><news:publication_date>2026-03-27T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Pearls & Perspectives: Rethinking Uroflowmetry with Innovation, with Bishara Korkor, MS]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/daniel-shapiro-md-on-emerging-biomarkers-combination-strategies-in-rcc</loc><lastmod>2026-03-26T17:39:05.196Z</lastmod><news:news><news:publication_date>2026-03-26T17:39:05.196Z</news:publication_date>
        <news:title><![CDATA[Daniel Shapiro, MD, on emerging biomarkers, combination strategies in RCC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/idmc-confirms-statistical-power-of-pivotal-quilt-2-005-trial-in-bcg-na-ve-nmibc</loc><lastmod>2026-03-26T14:00:06.740Z</lastmod><news:news><news:publication_date>2026-03-26T14:00:06.740Z</news:publication_date>
        <news:title><![CDATA[IDMC confirms statistical power of pivotal QUILT-2.005 trial in BCG-naïve NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/balancing-treatment-intensification-and-toxicity-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-03-26T12:15:00Z</lastmod><news:news><news:publication_date>2026-03-26T12:15:00Z</news:publication_date>
        <news:title><![CDATA[Balancing Treatment Intensification and Toxicity in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/treatment-intensification-across-disease-presentations-in-metastatic-castration-sensitive-prostate-cancer-mcspc-</loc><lastmod>2026-03-26T12:00:00Z</lastmod><news:news><news:publication_date>2026-03-26T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Treatment Intensification Across Disease Presentations in Metastatic Castration Sensitive Prostate Cancer (mCSPC) ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/anjali-kapur-md-highlights-post-market-safety-data-on-ecoin-itns-for-uui</loc><lastmod>2026-03-25T18:15:49.292Z</lastmod><news:news><news:publication_date>2026-03-25T18:15:49.292Z</news:publication_date>
        <news:title><![CDATA[Anjali Kapur, MD, highlights post-market safety data on eCoin ITNS for UUI]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/nccn-guidelines-adopt-ibcg-risk-model-for-intermediate-risk-nmibc</loc><lastmod>2026-03-25T15:15:51.073Z</lastmod><news:news><news:publication_date>2026-03-25T15:15:51.073Z</news:publication_date>
        <news:title><![CDATA[NCCN guidelines adopt IBCG risk model for intermediate-risk NMIBC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/capitello-281-pten-cut-off-analyses-and-disease-biology</loc><lastmod>2026-03-25T12:00:00Z</lastmod><news:news><news:publication_date>2026-03-25T12:00:00Z</news:publication_date>
        <news:title><![CDATA[CAPItello-281: PTEN Cut-Off Analyses and Disease Biology]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-approves-accelerated-thawing-method-for-nadofaragene-in-nmibc</loc><lastmod>2026-03-24T20:45:22.219Z</lastmod><news:news><news:publication_date>2026-03-24T20:45:22.219Z</news:publication_date>
        <news:title><![CDATA[FDA approves accelerated thawing method for nadofaragene in NMIBC ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/dietary-changes-and-medications-may-help-prevent-recurrent-nephrolithiasis</loc><lastmod>2026-03-24T18:15:53.773Z</lastmod><news:news><news:publication_date>2026-03-24T18:15:53.773Z</news:publication_date>
        <news:title><![CDATA[Dietary changes and medications may help prevent recurrent nephrolithiasis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/dalia-kaakour-md-on-cardiometabolic-risks-with-nhts-for-prostate-cancer</loc><lastmod>2026-03-24T16:00:40.304Z</lastmod><news:news><news:publication_date>2026-03-24T16:00:40.304Z</news:publication_date>
        <news:title><![CDATA[Dalia Kaakour, MD, on cardiometabolic risks with NHTs for prostate cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/who-benefits-most-from-adding-io-to-bcg-in-nmibc-</loc><lastmod>2026-03-24T14:30:22.166Z</lastmod><news:news><news:publication_date>2026-03-24T14:30:22.166Z</news:publication_date>
        <news:title><![CDATA[Who benefits most from adding IO to BCG in NMIBC?]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/chmp-recommends-eu-approval-of-3-month-formulation-of-leuprolide-mesylate</loc><lastmod>2026-03-23T17:00:06.416Z</lastmod><news:news><news:publication_date>2026-03-23T17:00:06.416Z</news:publication_date>
        <news:title><![CDATA[CHMP recommends EU approval of 3-month formulation of leuprolide mesylate]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/matthew-galsky-md-on-the-mechanism-of-action-of-fx-909-in-advanced-uc</loc><lastmod>2026-03-23T15:15:00Z</lastmod><news:news><news:publication_date>2026-03-23T15:15:00Z</news:publication_date>
        <news:title><![CDATA[Matthew Galsky, MD, on the mechanism of action of FX-909 in advanced UC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url></urlset>